Bortezomib EVER Pharma

Bortezomib EVER Pharma
Product Description

Bortezomib is a protease inhibitor indicated for the treatment of progressive or untreated multiple myeloma, and mantle cell lymphoma.

Bortezomib EVER Pharma is provided as a ready to useformulation for subcutaneous injection (SC), and afterdilution for intravenous injection.

EVER Pharma

  • AT
  • 2015
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Service
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)

EVER Pharma

  • AT
  • 2015
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Service
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)

More Products from EVER Pharma (12)

  • EVER Pharma Product List

    Product EVER Pharma Product List

    Our products include: Atosiban Cabazitaxel Cebrium(R) Cerebrolysin(R) Dacepton(R) Dexmedetomidine Docetaxel Fulvestrant MemoProve(R) Oxytocin Paclitaxel Pemetrexed Tachyben(R) Terlipressin
  • EVER Pharma: Product Portfolio

    Product EVER Pharma: Product Portfolio

    Our products include:  • Atosiban • Cabazitaxel • Cerbrium • Cerebrolysin • Dacepton/Apomorphine • Dexemedetomidine • Docetaxel • Fulvestrant • MemoProve • Oxytocin • Paclitaxel • Pemetrexed • Tachyben • Terlipressin • Trabectedin • Eribulin
  • Pemetrexed EVER Pharma

    Product Pemetrexed EVER Pharma

    Pemetrexed is an antineoplastic chemotherapy drug. It is used in the treatment of malignant mesothelioma and locally advanced or metastatic nonsquamous non-small cell lung cancer. - Available as a ready to dilute liquid formulation - does not require reconstitution from powder saving time and costs. It can...
  • Terlipressin EVER Pharma

    Product Terlipressin EVER Pharma

    - Ready to use product - for immediate use without reconstitution - Available in vials - safer and more convenient than ampoules - 5ml and new 10ml presentation covering initial and maintenance dose ranges - Additional indication - for Hepato-renal syndrome type I
  • Trabectedin EVER Pharma: 0.25mg + 1.0mg - LYO Vial

    Product Trabectedin EVER Pharma: 0.25mg + 1.0mg - LYO Vial

    - Available in 2 presentations – providing greater flexibility and convenience when preparing patient specific doses - All vial sizes come in CytoWrap® – for safer handling and transportation Description: Trabectedin is an antineoplastic chemotherapy drug. It is indicated as a monotherapy for the treatme...
  • Azacitidine EVER Pharma

    Product Azacitidine EVER Pharma

    Azacitidine is a cytotoxic hypomethylating chemical analogue of cytidine used in the treatment of myelodysplastic syndromes.

    Azacitidine EVER Pharma is available in both the standard 100 mg vial size and a new 150 mg vial size aligned to the most common patient doses to minimize waste...
  • Cabazitaxel EVER Pharma

    Product Cabazitaxel EVER Pharma

    Cabazitaxel is a third-generation antineoplastic taxane and was the fi rst therapy to show a survival benefi t for the treatment of patients with docetaxel-refractory mCRPC.

    Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in vial sizes&nbs...
  • Dexmedetomidine EVER Pharma

    Product Dexmedetomidine EVER Pharma

    Dexmedetomidine is a highly selective alpha-2 adrenergic receptor notable for its ability to provide sedation without the risk of respiratory depression.
    The first Dexmedetomidine in Europe indicated for both ICU and procedural sedation.
  • Fulvestrant EVER Pharma

    Product Fulvestrant EVER Pharma

    The first Fulvestrant in Europe approved for storageat room temperature.
  • Cabazitaxel EVER Pharma: 45mg/4.5ml + 50mg/5ml + 60mg/60ml - Single liquid vial

    Product Cabazitaxel EVER Pharma: 45mg/4.5ml + 50mg/5ml + 60mg/60ml - Single liquid vial

    Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in vial sizes covering the common range of patient specifi c doses for economy and convenience Cabazitaxel is a third-generation antineoplastic taxane and was the fi rst therapy to show a survival benefi t f...
  • CDMO: Contract Development

    Product CDMO: Contract Development

    EVER is a leader in pharmaceutical development


    Our end-to-end service covers every aspect of pharmaceutical development, from API selection to final process validation and quality assurance, with the highest level of expertise.

    With ‘state of the art’ labs in Unterach ...
  • CDMO: Contract Manufacturing

    Product CDMO: Contract Manufacturing

    EVER Pharma is a specialist in the manufacture of complex injectable products such as low oxygen formulations, crystal suspensions and oily solutions. This includes many highly active substances such as narcotics, hormones and cytotoxics.

    Our state-of-the-art facility utilizes the latest innovatio...

EVER Pharma resources (2)

  • News EVER Pharma gains EU Marketing Authorization for Trabectedin

    EVER Pharma announces the EU-wide marketing authorization of Trabectedin (in 0.25MG and 1MG vial sizes) for the treatment of advanced soft tissue sarcoma and ovarian cancer
  • Technical Data EVER Pharma: Product list of speciality injectables

    EVER Pharma's products include: Atosiban --  7.5 mg/ml Solution for Injection/InfusionAzacitidine -- 25 mg/ml Powder for Suspension for InjectionCabazitaxel -- 10 mg/ml - Solution for InfusionCerebrolysin® -- 215.2 mg/ml - Solution for Infusion Concentrate for Solution for InfusionDacepton (Apomorphine) -- 5 mg/ml & 10 mg/ml -  Solution for Injection/InfusionDexmedetomidine -- 100 µg/ml - Concentrate for Solution for InfusionDocetaxel -- 20 mg/ml - Concentrate for injectionFulvestrant -- 50 mg/ml - Ready to use pre-filled syringeOxytocin -- 5 IU/ml & 10 IU/ml - Solution for Injection/InfusionPaclitaxel-- 6 mg/ml - Concentrate for InjectionPemetrexed -- 25 mg/ml - Concentrate for Solution for InfusionTerlipressin -- 0.17 mg/ml - Solution for Injection/Infusion